Hepatitis Monthly

Published by: Kowsar

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy

Kamuran Turker 1 , * , Betul Tas 2 , Murat Ozkaya 3 , Ebru Tas 4 , Aysel Caglar 5 and Umit Seza Tetikkurt 5
Authors Information
1 Department of Infectious Diseases, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey
2 Department of Dermatology, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey
3 Department of Physical Medicine and Rehabilitation, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey
4 Department of Gastroenterology, Dumlupinari University Faculty of Medicine, Evliya Celebi Research and Training Hospital, Kutahya, Turkey
5 Department of Pathology, Ministry of Health Bagcilar State Hospital, Istanbul, Turkey
Article information
  • Hepatitis Monthly: March 31, 2015, 15 (3); e24804
  • Published Online: March 20, 2015
  • Article Type: Case Report
  • Received: October 27, 2014
  • Revised: January 26, 2015
  • Accepted: February 4, 2015
  • DOI: 10.5812/hepatmon.24804

To Cite: Turker K, Tas B, Ozkaya M, Tas E, Caglar A, et al. Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy, Hepat Mon. 2015 ;15(3):e24804. doi: 10.5812/hepatmon.24804.

Copyright: Copyright © 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2007; 19(9): 817-20[DOI][PubMed]
  • 2. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009; 23(10): 677-83[PubMed]
  • 3. Bouhanna P. [The tractiophototrichogram, an objective method for evaluating hair loss]. Ann Dermatol Venereol. 1988; 115(6-7): 759-64[PubMed]
  • 4. Orfanos CE. Androgenetic alopecia : Clinical aspect and treatment in Orfanos CE, Happle R Hair and hair Diseases. 1990; : 485 – 527
  • 5. Serrano-Falcon C, Fernandez-Pugnaire MA, Serrano-Ortega S. Hair and scalp evaluation: the trichogram. Actas Dermosifiliogr. 2013; 104(10): 867-76[DOI][PubMed]
  • 6. Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002; 205(3): 300-1[PubMed]
  • 7. Yun SJ, Kim SJ. Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation. Dermatology. 2007; 215(1): 36-40[DOI][PubMed]
  • 8. Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010; 15(7): 5-7[PubMed]
  • 9. Omazzi B, Prada A, Borroni G, Sacrini F. Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review. Hepatol Res. 2012; 42(12): 1248-51[DOI][PubMed]
  • 10. Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon-induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010; 49(7): 829-33[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader